NGM120 Clinical Trials (2026): 3 Studies for Colorectal Cancer & Cachexia
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
3 NGM120 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Colorectal Cancer & Cachexia) and 317 total planned enrollment. 1 NGM120 clinical trial is actively recruiting at 12 U.S. sites across 8 states. Most recent activity: NCT07033026 (Dec 2027).
Where to Participate: All NGM120 Trial Sites in the U.S. (12 sites across 8 states)
Every actively recruiting NGM120trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | NGM Clinical Study Site | Los Angeles90033 | NCT07033026 | Map |
| CA | NGM Clinical Study Site | Los Angeles90095 | NCT07033026 | Map |
| CA | NGM Clinical Study Site | Santa Rosa95403 | NCT07033026 | Map |
| FL | NGM Clinical Study Site | Margate33063 | NCT07033026 | Map |
| MD | NGM Clinical Study Site | Baltimore21201 | NCT07033026 | Map |
| NY | NGM Clinical Study Site | New York10065 | NCT07033026 | Map |
| OH | NGM Clinical Study Site | Toledo43608 | NCT07033026 | Map |
| OH | NGM Clinical Study Site | Youngstown44504 | NCT07033026 | Map |
| TX | NGM Clinical Study Site | Dallas75390 | NCT07033026 | Map |
| TX | NGM Clinical Study Site | Laredo78041 | NCT07033026 | Map |
| VA | NGM Clinical Study Site | Richmond23114 | NCT07033026 | Map |
| WI | NGM Clinical Study Site | Appleton54915 | NCT07033026 | Map |
NGM120 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | Total |
|---|---|---|---|
| P1 | 1 | 1 | |
| P1/P2 | 1 | 1 | |
| P2 | 1 | 1 |
Recruiting NGM120 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07033026 | An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia. | P2 | Colorectal Cancer | 136 | Jun 2025 |
NGM120 clinical trials by indication
Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07033026 | — | P2 | recruiting | An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia. |
Pancreatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04068896 | — | P1/P2 | completed | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy |
Cachexia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03392116 | — | P1 | completed | Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects |
All NGM120 trials (3)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07033026 | An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia. | P2 | recruiting | 136 | NGM Biopharmaceuticals, Inc | Jun 2025 | |
| NCT04068896 | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | P1/P2 | completed | 89 | NGM Biopharmaceuticals, Inc | Oct 2019 | |
| NCT03392116 | Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects | P1 | completed | 92 | NGM Biopharmaceuticals, Inc | Jan 2018 |
NGM120 clinical trials: frequently asked questions
- How many NGM120 clinical trials are there?
- 3 NGM120 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 2 are marked completed.
- Are NGM120 clinical trials recruiting in 2026?
- Yes — 1 NGM120 trial is actively recruiting in 2026, with 12 U.S. sites across 8 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is NGM120 being studied for?
- NGM120 is being studied for Colorectal Cancer, Cachexia, Cancer Cachexia, CRC (Colorectal Cancer), Esophageal Cancer and 9 more. The trials are grouped by indication on this page.
- What phase is NGM120 in?
- NGM120 clinical trials span 1 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors NGM120 clinical trials?
- The lead sponsor across the most NGM120 trials is NGM Biopharmaceuticals, Inc. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming NGM120as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: